bioRxivCancer BiologyPreprint
Aberrant oxidative metabolism selects for TET2-deficient hematopoietic stem and progenitor cells
Katia E. NiñoiD, Vera AdemàiD, Alyx E. Gray, Courtney M Cowan, Wolfgang E. SchleicheriD, Mohsen HosseiniiD, Sierra N. Bennett, Sweta B. PateliD, Steven MoreiraiD, Etienne P. DanisiD, Feyiang MaiD, Hsin-Ying Lin, Tracy N. YoungiD, Colin A. Anderson, Devyani SharmaiD, Angelica VaresiiD, Marie–Dominique FilippiiD, Keisuke ItoiD, Meelad M. DawlatyiD, Gang Huang, Julie A. ReisziD, Stephanie Zhi-Juan XieiD, Steven M. ChaniD, Lin TaniD, Guillermo Garcia‐ManeroiD, , Eric Martin PietrasiD
Abstract
The mechanism(s) driving selective expansion of mutant hematopoietic stem and progenitor cells (HSPC) in clonal hematopoiesis (CH) are incompletely understood. Here, we address the role of metabolism in selection for HSPC with loss of function mutations in TET2. Loss of Tet2 in murine HSPC triggers overexpression of glycolysis and oxidative phosphorylation genes and increased oxidative metabolism via an enlarged mitochondrial network. However, Tet2-deficient HSPC maintain a normal redox state. Strikingly, compound loss of the rate-limiting pentose phosphate pathway (PPP) enzyme glucose-6-phosphate dehydrogenase (G6PD) triggers increased reactive oxygen species and impairs the fitness of Tet2-deficient HSPC. We find that aberrant oxidative metabolism is also a feature of HSPC in human CH and clonal cytopenia of unknown significance (CCUS). Overall, our data point to aberrant metabolism as a critical and conserved driver of selection in TET2-deficient CH and identify the PPP as a crucial compensatory pathway needed to maintain their selective advantage. Statement of SignificanceThis study identifies oxidative metabolism as a critical driver of selection for TET2-deficient HSPC in clonal hematopoiesis (CH). It also demonstrates that cellular redox state is a vulnerability that impairs their fitness. These insights establish targetable metabolic pathway(s) that could be exploited in the setting of TET2 mutant CH.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- research focus: chromatin & epigenetic regulation
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- STING-dependent cytosolic DNA sensing pathway drives the progression to leukemia in TET2-mutated HSPCs
- TET2-mutant clonal hematopoiesis prevents T-cell exhaustion and suppresses cancer metastasis
Ai Nhan Thi Le, Manabu Fujisawa, … Mamiko Sakata‐Yanagimoto·bioRxiv·Mar 11, 2026
- Cell of origin epigenetic priming determines susceptibility to Tet2 mutation
G. Schiroli, V. K. Kartha, … D. T. Scadden·bioRxiv·Sep 4, 2023
- Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
N. A. Jakobsen, S. Turkalj, … P. Vyas·bioRxiv·Sep 12, 2023
- Cell-type specific requirement for pyruvate dehydrogenase in hematopoiesis and leukemia development.
S. Jun, S. Mahesula, … M. Agathocleous·bioRxiv·May 4, 2021
- Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells by XPO1 inhibitors
C. Jing, N. Prutsch, … A. T. W. Look·bioRxiv·Oct 12, 2022